Muraglitazar

Muraglitazar (proposed tradename Pargluva) is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ.^[1]

Other names2-[(4-Methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid

ATC code

• None

Legal status

• Development terminated

CAS Number

• 331741-94-7 ^Y

Quick facts Clinical data, Other names ...

Muraglitazar

Clinical data
Other names	2-[(4-Methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid
ATC code	None
Legal status
Legal status	Development terminated
Identifiers
IUPAC name N-[(4-Methoxyphenoxy)carbonyl]-N-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]benzyl}glycine
CAS Number	331741-94-7 Y
PubChem CID	206044
ChemSpider	178524 N
UNII	W1MKM70WQI
KEGG	D05091 Y
ChEMBL	ChEMBL557580 N
CompTox Dashboard (EPA)	DTXSID9057719
Chemical and physical data
Formula	C29H28N2O7
Molar mass	516.550 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC
InChI InChI=1S/C29H28N2O7/c1-20-26(30-28(37-20)22-6-4-3-5-7-22)16-17-36-24-10-8-21(9-11-24)18-31(19-27(32)33)29(34)38-25-14-12-23(35-2)13-15-25/h3-15H,16-19H2,1-2H3,(H,32,33) N Key:IRLWJILLXJGJTD-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Close

The drug had completed phase III clinical trials,^[2] however in May 2006 Bristol-Myers Squibb announced that it had discontinued further development.^[3]

Data on muraglitazar is relatively sparse due to the brief introduction and subsequent abandonment of this agent. One double-blind randomized clinical trial^[2] comparing muraglitazar and pioglitazone found that the effects of the former were favourable in terms of HDL-C increase, decrease in total cholesterol, apolipoprotein B, triglycerides and a greater reduction in HbA_1c (p <0.0001 for all comparisons). However, the muraglitazar group had a higher all-cause mortality, greater incidence of edema and heart failure and more weight gain compared to the pioglitazone group. A meta-analysis of the phase II and III clinical trials of muraglitazar revealed that it was associated with a greater incidence of myocardial infarction, stroke, transient ischemic attacks and congestive heart failure (CHF) when compared to placebo or pioglitazone.^[4]